Oct 07 99 New Treatment For Multiple Sclerosis
A plasma exchange procedure developed by physicians at Mayo Clinic, Rochester, MN, improved symptoms such as paralysis and loss of speech for 42 percent of patients with multiple sclerosis who had experienced flare-ups.
Sep 21 99 Washington DC Voted in Favor of Medical Marijuana
Residents of the nation's capital overwhelmingly voted to legalize marijuana use for medical purposes, according to year-old ballot results released for the first time on Monday after months of controversy.
Sep 17 99 New Treatment Options for Multiple Sclerosis
Mayo Clinic neurologists today reported the results of a new treatment option that was effective in over 40 percent of patients with severe attacks of multiple sclerosis and related diseases that cause inflammation and myelin destruction in the brain and spinal cord.
Sep 14 99 Berlex Halts Betaseron Study
Berlex Laboratories, the Montville, New Jersey-based unit of Germany's Schering AG, said on Monday that it would stop its ongoing US study of interferon beta 1-b (Betaseron) for treatment of secondary progressive multiple sclerosis, based on the recommendation of the Independent Monitoring Board.
Aug 04 99 Hepatitis B Vaccination Should Be Avoided in Patients With Risk of CNS Disease
French researchers report eight cases in which patients developed central nervous system inflammation and demyelinating disease less than 10 weeks after receiving a hepatitis B vaccination.
Apr 23 99 Pneumonia May Play Role in Development of MS
An agent that causes respiratory tract infections such as community-acquired pneumonia, called Chlamydia pneumoniae, may be a factor in the development of multiple sclerosis (MS) in some patients.
Feb 27 99 Multiple Sclerosis Drugs Have A High Cost/QALY
Using the results of major trials, this report compares 4 products available for the treatment of MS: 'Avonex' [interferon-beta-1a], 'Rebif' [interferon-beta-1a], 'Betaseron' [interferon-beta-1b] and 'Copaxone' [glatiramer acetate].